Aims-To develop a specific test for lupus anticoagulant activity with reduced sensitivity to coagulation factor deficiency that would be suitable for analysis of plasmas from patients receiving oral anticoagulants. Methods 
TSVT were established and a reference range was determined in normal healthy subjects. Results were considered positive for lupus anticoagulant if the ratio was .1-1 and was reduced by .10% or to <II in the PNP. In 43 samples from patients receiving oral anticoagulants there was no correlation between level of anticoagulation and TSVT, and only seven samples had increased TSVTs. Of these, five corrected on mixing with normal plasma and two gave equivocal results. The patients with mild liver dysfunction all had normal TSVTs. The TSVT in plasmas from patients receiving heparin correlated with the heparin concentrations (as measured by the APTT, r2 = 0.81). Some anticoagulated plasmas showed correction in the PNP and were regarded as false positive. Fourteen of 17 patients known to have lupus anticoagulant (on the basis of DRWT results) were also positive by the TSVT; two of the remaining three were borderline and one was negative. Conclusions-The TSVT showed satisfactory intra-assay precision and reasonable sensitivity to lupus anticoagulant, compared with the DRVVT. The TSVT was influenced by the presence of heparin but was not sensitive to the effects of oral anticoagulant. Like other lupus anticoagulant tests, it does not seem to havea 100% detection rate, but this may be due to the presence of lupus anticoagulant subtypes with distinct activities or the requirement of cofactors other than prothrombin or 112 glycoprotein-I. (7 Clin Pathol 1994; 47:497-501) The lupus anticoagulant prolongs the clotting times of phospholipid dependent in vitro coagulation tests.' This is due to the presence of plasma immunoglobulins ( comparable performance to the "in house" reagent.
The stability of the Taipan reagent was assessed by measuring the TSVT of a lupus anticoagulant plasma at varying time intervals over an eight hour period using Taipan venom reagent that was stored on ice during this period or repeatedly freeze-thawed. The Taipan venom reagent remained stable on ice and was unaffected by repeated freeze-thawing (table 1) . Three different batches of TSV were tested and demonstrated a similar potency and gave a similar pattern of results with normal and lupus anticoagulant positive plasmas.
Intra-assay precision of the optimised TSVT was assessed by assaying normal plasma and a well characterised lupus anticoagulant plasma 20 times. The intra-assay coefficients of variation (CV) of ratios of the TSVT and PNP of the lupus anticoagulant plasma were determined to be 4% and 3%, respectively. The interassay precision was assessed by assaying a separate aliquot of an lupus anticoagulant plasma on nine consecutive runs over a six week period and was determined to be 13% and 7-3% for the TSVT and PNP, respectively. Although a certain degree of interassay variation was apparent in both the normal and lupus anticoagulant positive plasmas, the lupus anticoagulant plasma was correctly identified on each occasion.
The optimised method was used to mea- 2) . Thirty six of the patients receiving warfarin had normal TSVT ratios, irrespective of INR, and seven plasmas from five patients had increased TSVT ratios. Of the seven plasmas with increased TSVT ratios, two corrected by more than 10% or to < 1 1 in the PNP. These plasmas also corrected to <1 1 (case 1) and by more than 10% (case 2) in a 1:1 mix with normal plasma and so were considered as possible lupus anticoagulant positive plasmas (table 2) . Five plasmas did not correct with PNP and of these, four were found to correct when a 1:1 with normal plasma was tested, indicating that prolongation of the TSVT was due to factor deficiency.
The remaining plasma was not tested with a 1:1 mix with normal plasma but was from a Nine plasmas from seven patients receiving unfractionated heparin and selected at random were tested to examine the effect of heparin on the TSVT (fig 3) . Heparin resulted in prolongation of the TSVT and a significant correlation was demonstrated between APTT ratio and TSVT (r' = 0-81, p <0.001). Five patients had TSVT ratios of 2 1 1 and in three of these the PNP corrected the TSVT ratio by more than 10%, giving an apparent positive result, while the remaining two patients corrected by <10%.
Twelve patients with liver dysfunction (secondary to alcoholic liver disease, paracetamol overdose, or obstructive jaundice) with a mean INR of 1-52 (range 1.12-2-19) and thrombin time of 15-5 (range 13-0-19-0) were tested. All patients had normal TSVT ratios (not shown).
We also investigated 17 patients who had been diagnosed as lupus anticoagulant positive on the basis of DRVVT results. The median DRVVT and TSVT results are shown in table 3. Fourteen patients were found to be positive for lupus anticoagulant by the TSVT. Of the remaining three, one had a normal TSVT (1 -06), one had a borderline TSVT (1 -09) which corrected with the PNP (1 -00), and one had a prolonged TSVT (1.23) but gave <10% correction with the PNP (1-14) .
We also tested 16 patients attending the thrombophilia clinic for investigation of previous thrombotic episodes who had abnormal DRVVTs but did not demonstrate the correction patterns typical of lupus anticoagulant. Ten of these patients had normal TSVT results. The remaining six patients all showed >10% correction with PNP but also demonstrated >10% correction in a 1:1 mix with normal plasma. Thus the TSVT allowed 10 of these patients to be classified as lupus anticoagulant negative but could not clarify the situation in the remainder.
Discussion
The clinical importance of antiphospholipid antibodies is becoming increasingly recognised and consequently lupus anticoagulant testing has become an essential routine procedure for haemostasis laboratories. The action of lupus anticoagulant is universally agreed to centre on the inhibition of the role of phospholipid in haemostatic reactions. Therefore, the amount of phospholipid in a test system should be limited, as high phospholipid concentrations may mask the inhibitory effect of lupus anticoagulants. In the TSVT a 1 in 4 dilution of phospholipid resulted in good distinction between normal and lupus anticoagulant plasma clotting times, whereas higher dilutions resulted in very long clotting times, giving logistical problems for routine use and weaker clot formation, which made accurate end-point determination difficult. Confirmation of the presence of lupus anticoagulant requires correction of the clotting time on addition of lysed washed platelets or excess phospholipid, but no correction on mixing with normal plasma.' 13 A 1 in 4 dilution of the stock suspension of washed platelets was selected for use and gave good correction (>20%) of the TSVT ratio using a well characterised lupus anticoagulant plasma. Preparation of washed platelets is time consuming and so two commercial products designed for use in the PNP in the APIT or DRVVT were tested in the TSVT and performed well.
One of the disadvantages of the DRVVT is that the RVV is unstable and activity is reduced over time, even at 4GC.'4 The results of assays performed with TSV stored on ice over an eight hour period or repeatedly freezethawed suggest that TSV is stable, even in a diluted form. This may be due to the incorporation of albumin or other stabilisers by the manufacturer in the particular TSV reagent used. This may not be the case with other products and therefore TSV stability may vary according to source.
Prolongation of the TSVT was generally not related to the degree of oral anticoagulant treatment; the TSVT was normal in two patients with grossly raised INR values (8-4 and 14.2). Five anticoagulated patients did have prolonged TSVTs and of these, three corrected to <1 1 with a 50/50 mix with normal plasma, indicating that the prolongation was due to factor deficiency. These patients might have had more severely depressed prothrombin concentrations as a result of concomitant liver dysfunction. In the remaining two, the TSVT corrected in the PNP and so they must be considered as possible lupus anticoagulant positive patients.
A number of patients with mild liver dysfunction were tested by the TSVT. All patients had normal TSVT results, suggesting that the fibrinogen and vitamin K dependent coagulation factor abnormalities induced by this condition do not adversely affect the TSVT.
A correlation was shown between heparin treatment (as measured by the APFT) and TSVT. Although prolongation of the TSVT and PNP was demonstrated with increased heparin concentrations the PNP was less prolonged than the TSVT at the higher heparin values, giving a false positive effect. This is most likely attributable to the heparin neutralising activity of platelet factor 4 in the washed platelet preparation. Plasmas contaminated with heparin therefore cannot be reliably tested using the TSVT and testing should be repeated when heparin treatment has been stopped.
The efficacy of the TSVT in identifying lupus anticoagulant positive plasmas was assessed by testing known lupus anticoagulant positive plasmas. The patient group comprised patients with SLE and antiphospholipid syndrome and included some patients receiving oral anticoagulant treatment. The minimum and median values of the DRVVT and TSVT were comparable but the maximum level of the TSVT was much lower than that of the DRVVT. This difference is most likely a reflection of the reduced sensitivity of the TSVT to oral anticoagulants. The TSVT correctly identified all but one of the lupus anticoagulant positive plasmas. This plasma did not fulfil the lupus anticoagulant criteria of the TSVT but was identified as lupus anticoagulant positive using the DRVVT. The reason for this discrepancy is unclear; it is possible that the lupus anticoagulant may be part of a distinct subgroup with its main mode of action directed at a site other than the prothrombinase complex which forms the basis of the TSVT.
The TSVT was also used to test several plasmas which gave prolonged DRVVT results but did not give correction results typical of lupus anticoagulant. Most of these plasmas yielded normal TSVTs. Plasmas demonstrating prolonged TSVTs all showed correction with a 50/50 mix with normal plasma and correction with PNP. These results show that the TSVT is far less liable to false positive analysis than the DRVVT.
The TSVT can therefore be considered a suitable test for the diagnosis of lupus anticoagulant. The TSVT demonstrated satisfactory intra-assay precision and reasonable sensitivity compared with the DRVVT. It has the advantage of requiring only adequate fibrinogen and prothrombin concentrations and has reduced sensitivity to factor deficiency, an important consideration in the analysis of plasmas from patients receiving oral anticoagulants. An additional advantage is that the test is based on prothrombin, a relatively nonlabile coagulation factor, and as such may be more readily applied than the DRVVT to the assay of previously freeze-thawed plasmas. The test is easy to perform, readily adaptable for automated operation, and relatively inexpensive and is therefore suitable for use in most haemostasis laboratories.
